In:
Hemodialysis International, Wiley, Vol. 19, No. 2 ( 2015-04), p. 235-241
Abstract:
Nocturnal home hemodialysis ( NHHD ) has shown promising results in various clinical parameters. Whether NHHD provide benefit in anemia management remains controversial. This study aims to investigate whether anemia and erythropoiesis‐stimulating agent ( ESA ) requirement are improved in patients receiving alternate night NHHD compared with conventional hemodialysis ( CHD ). In this retrospective controlled study, a clinical data of 23 patients receiving NHHD were compared with 25 in‐center CHD patients. Hemoglobin level, ESA requirement, iron profile, and dialysis adequacy indexes were compared between the two groups. Hemoglobin level increased from baseline of 9.37 ± 1.39 g/ dL to 11.34 ± 2.41 g/ dL at 24 months ( P 〈 0.001) and ESA requirement decreased from 103.44 ± 53.55 U /kg/week to 47.33 ± 50.62 U /kg/week ( P 〈 0.001) in NHHD patients. ESA requirement further reduced after the first year of NHHD ( P = 0.037). Standard Kt/V increased from baseline of 2.02 ± 0.28 to 3.52 ± 0.30 at 24 months ( P 〈 0.001). At 24 months, hemoglobin level increased by 1.98 ± 2.74 g/ dL in the NHHD group while it decreased by 0.20 ± 2.32 g/ dL in the CHD group ( P = 0.007). ESA requirement decreased by 53.49 ± 55.50 U /kg/week in NHHD patients whereas it increased by 16.22 ± 50.01 U /kg/week in CHD patients ( P 〈 0.001). Twenty‐six percent of NHHD patients were able to stop ESA compared with none in the CHD group. Standard Kt/V showed greater increase in the NHHD group. (1.49 ± 0.36 in NHHD vs. 0.18 ± 0.31 in CHD , P = 0.005). NHHD with an alternate night schedule improves anemia and reduces ESA requirement as a result of enhanced uremic clearance. This benefit extended beyond the first year of NHHD .
Type of Medium:
Online Resource
ISSN:
1492-7535
,
1542-4758
DOI:
10.1111/hdi.2015.19.issue-2
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2103570-2
